Last reviewed · How we verify
Lisinopril/HCTZ (HCTZ)
Lisinopril/HCTZ is a fixed-dose combination medication consisting of a thiazide diuretic (HCTZ) and an angiotensin-converting enzyme (ACE) inhibitor (Lisinopril). It is used to treat hypertension, stroke, myocardial infarction, cardiovascular mortality, diabetes, hyperlipidemia, angina, and heart failure. The medication is a small molecule and its commercial status is owned by Direct_Rx. Lisinopril/HCTZ works by increasing urine production and reducing blood pressure through its diuretic effect and inhibiting the conversion of angiotensin I to angiotensin II. Key safety considerations include monitoring of potassium levels and potential interactions with other medications.
At a glance
| Generic name | HCTZ |
|---|---|
| Also known as | Hydrochlorothiazide, Hydrochlorothorazide, hydrochlorothiazice, water pill, Hydrochlorthiazide, Aquazide H |
| Sponsor | Direct_Rx |
| Drug class | Thiazide Diuretic [EPC] |
| Modality | Small molecule |
| Therapeutic area | Metabolic |
| Phase | FDA-approved |
Approved indications
- hypertension
- stroke
- myocardial infarction
- cardiovascular mortality
- diabetes
- hyperlipidemia
- angina
- heart failure
- diabetic kidney disease
Boxed warnings
- WARNING: FETAL TOXICITY • When pregnancy is detected, discontinue lisinopril and hydrochlorothiazide tablets as soon as possible. • Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus. See Warnings, Fetal Toxicity.
Common side effects
- dizziness
- headache
- cough
- fatigue
- orthostatic effects
- diarrhea
- nausea
- upper respiratory infection
- muscle cramps
- asthenia
- paresthesia
- hypotension
Key clinical trials
- POcus INTERvention for Tailoring Diuretic Strategy in Acute Decompensated Heart Failure (PHASE2,PHASE3)
- Triple Antihypertensive Medication After Intracerebral Hemorrhage for Blood Pressure Control (NA)
- HYDROchlorothiazide to PROTECT Polycystic Kidney Disease Patients and Improve Their Quality of Life (PHASE3)
- Study to Evaluate the Efficacy and Safety of TEL/AML/CTD in Elderly Patients With Essential Hypertension (PHASE4)
- Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants
- Protocol of Diuretics Use in Congestive Therapy in Heart Failure (PHASE4)
- Integration of Hypertension Management in HIV Care in Uganda (NA)
- Diuretics and Volume Overload in Early CKD (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Lisinopril/HCTZ CI brief — competitive landscape report
- Lisinopril/HCTZ updates RSS · CI watch RSS
- Direct_Rx portfolio CI